Randomized trial · people

Tirzepatide 15 mg: 14.7% weight loss at 72 weeks in SURMOUNT-2

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with obesity and type 2 diabetes, both tirzepatide doses tested led to far more weight loss than placebo over 72 weeks, with mainly gut-related side effects.

Kind
Randomized trial
Studied in
People
Number studied
938
Published
2023
Journal
Lancet

What they tested

Does weekly tirzepatide help adults with obesity and type 2 diabetes lose weight compared with placebo, and how safe is it?

How the study was done

A double-blind, randomized, placebo-controlled phase 3 trial in 938 adults across seven countries with a BMI of 27 kg/m2 or higher and HbA1c (a 3-month average of blood sugar) of 7-10%. They got weekly tirzepatide shots under the skin at 10 mg or 15 mg, or placebo (a dummy shot), for 72 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 72, average bodyweight change was -12.8% in the 10 mg arm, -14.7% in the 15 mg arm and -3.2% on placebo. That put the 10 mg arm -9.6 percentage points and the 15 mg arm -11.6 percentage points ahead of placebo. Between 79% and 83% of people on tirzepatide lost at least 5% of their weight, against 32% on placebo. Side effects were mostly gut-related, such as nausea, diarrhea and vomiting, and mostly mild to moderate; fewer than 5% stopped treatment because of them, 68 people (7%) overall had a serious adverse event, and the 2 deaths in the 10 mg arm were judged by the investigator to be unrelated to the drug.

What it doesn’t show

Everyone in the trial had type 2 diabetes with HbA1c of 7-10%, so the results apply to that group, and it ran for 72 weeks. The trial was funded by Eli Lilly and Company.

The paper

Garvey et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo